The Microcirculation in Acute Myocardial Infarction (Micro-AMI)

STEMI Clinical Trial

— Micro-AMI  

Official title:

The Microcirculation in Acute Myocardial Infarction (Micro-AMI)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01552564
• Other study ID #: 1625
• Status: Completed
• Phase: N/A
• First received: March 9, 2012
• Last updated: October 27, 2014
• Start date: March 2012

Study information

• Verified date: October 2014
• Source: University of Bristol
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: National Institute for Health Research
• Study type: Observational

Clinical Trial Summary

This study investigates the association between the microvascular resistance at the time of primary percutaneous intervention, with microvascular obstruction on CMR and blood markers of myocardial damage.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. primary completion date: January 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• >18 years old

• Cardiac symptoms of > 20 mins chest pain or equivalent.

• ECG criteria consistent with STEMI (STEMI)

• Proceeding with percutaneous angioplasty

• Assent/ consent to the study

Exclusion Criteria:

• Known allergy to adenosine or gadolinium

• Chronic atrial fibrillation

• Renal impairment with eGFR <30

• Contraindication to angiography

• Contraindication to CMR (implanted pacemaker/ defibrillator, ferromagnetic metal implant/ injury, claustrophobia, obesity/ too large for CMR scanner)

• Cardiogenic shock

• Patients with special communication needs or altered consciousness.

• Patients who do not give assent/consent to the study

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Myocardial Infarction
• STEMI

Intervention

Procedure:
• Index of microvascular resistance

Other:
• Cardiac magnetic resonance

• Blood markers

Locations

Country	Name	City	State
United Kingdom	Bristol Heart Institute	Bristol

Sponsors (1)

Lead Sponsor	Collaborator
University of Bristol

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Microvascular obstruction	Microvascular obstruction as a percentage of the left ventricle at 2-4 days.	DAy 2-4	No